Ultimovacs finalize topline data for ph2 cancer vaccine trialUltimovacs is a norwegian clinical phase biotech with a universal cancer vaccine as its lead product.
Today the company reported to the market that in march it will share topline data from its randomized phase 2 trial INITIUM for its lead product UV1 , a universal cancer vaccine to be used i